Viatris Inc. (NASDAQ:VTRS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 9, Barclays ...

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically ...

Viatris Inc. (VTRS) delivered second-quarter 2025 adjusted earnings of 62 cents per share, which beat the Zacks Consensus Estimate of 56 cents. The company recorded adjusted earnings of 69 cents per ...

Canonsburg, Pennsylvania-based Viatris Inc. (VTRS) is a healthcare company that provides a diverse portfolio of branded, generic, and complex medicines to patients. Valued at a market cap of $13.4 ...

Viatris stock moves and what is driving sentiment Viatris (VTRS) has quietly climbed about 14% over the past month and roughly 21% in the past 3 months, even though the share price is still slightly ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Viatris (NASDAQ:VTRS) shares recorded modest gains in the premarket on Thursday after the Xanax maker announced positive outcomes to several Phase 3 trials alongside better-than-expected financials ...

Viatris faces revenue declines, execution issues, and high debt post-merger. Click here to read my latest analysis of VTRS ...

On this news, the price of Viatris stock declined roughly 15% during the trading day, from a closing price of $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025.

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company ...

Did you lose money on investments in Viatris? If so, please visit Viatris Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your ...